Informazioni sul prodotto
- 1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one
- 1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 2H-benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-
- 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
Akti-1/2 is a potential anticancer agent that inhibits growth and induces apoptosis in cancer cells. Akti-1/2 has been shown to induce autophagy, which is the process by which cells degrade cellular components, leading to increased mitochondrial membrane potential and inhibition of cell death. Akti-1/2 also activates cyclin D2 and MCL-1 protein expression, which are important for cell cycle progression. Akti-1/2 has inhibitory properties against the proliferation of cancer cells in vitro and synergistic effects with chemical inhibitors. This drug may be useful for the treatment of eye disorders such as macular degeneration or retinitis pigmentosa.
Proprietà chimiche
Richiesta tecnica su: 3D-FA17246 Akti-1/2
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.